Aurinia Pharmaceuticals Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 28.19 million compared to USD 6.62 million a year ago. Net loss was USD 35.52 million compared to USD 47.01 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.37 a year ago.
For the six months, revenue was USD 49.82 million compared to USD 7.53 million a year ago. Net loss was USD 73.15 million compared to USD 97.39 million a year ago. Basic loss per share from continuing operations was USD 0.52 compared to USD 0.76 a year ago.